Brain lipoprotein metabolism and its relation to neurodegenerative disease

Critical Reviews in Neurobiology

Volumn 13, Issue 4, 1999, Pages 357-407

  Danik, M ^a   Champagne, D ^a   Petit Turcotte, C ^a   Beffert, U ^a   Poirier, J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Apolipoprotein; Brain injury; Central nervous system; Cerebrospinal fluid; Lipids

Indexed keywords

APOLIPOPROTEIN D; APOLIPOPROTEIN E; CARRIER PROTEIN; CELL SURFACE RECEPTOR; CHOLESTEROL; CLUSTERIN; ENZYME; LIPOPROTEIN;

ALZHEIMER DISEASE; BILE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHOLESTEROL TRANSPORT; DEGENERATIVE DISEASE; ENERGY RESOURCE; EPENDYMA CELL; HUMAN; LIPOPHILICITY; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; MEMBRANE; NERVE CELL; NERVOUS TISSUE; OXIDATION; PATHOPHYSIOLOGY; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE; TURNOVER TIME;

EID: 0033303337     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v13.i4.20     Document Type: Review

References (458)

1. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The framingham study
2. LDL-cholesterol: A risk factor for coronary artery disease - From epidemiology to clinical trials
3. Plasma triglyceride as a risk factor for cardiovascular disease
4. Pathway of cholesterol efflux from human hepatoma cells
5. Hepatic apolipoprotein J is secreted as a lipoprotein
6. Identification and partial characterization of discrete apolipoprotein A-containing lipoprotein particles secreted by human hepatoma cell line HepG2
7. Binding and degradation of human high-density lipoproteins by human hepatoma cell line HepG2
8. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids
9. Hepatic uptake of chylomicron remnants
10. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
11. The role of factors that regulate the synthesis and secretion of very-low-density lipoprotein by hepatocytes
12. Caco-2 cells as a model for intestinal lipoprotein synthesis and secretion
13. Human granulosa cells use high density lipoprotein cholesterol for steroidogenesis
14. A receptor-mediated pathway for cholesterol homeostasis
15. The LDL-receptor-related protein LRP, is an apolipoprotein E-binding protein
16. Efflux of lipid from fibroblasts to apolipoproteins: Dependence on elevated levels of cellular unesterified cholesterol
17. Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cells
18. Differential effect of subspecies of lipoprotein containing apolipoprotein A-I on cholesterol efflux from cholesterol-loaded macrophages: Functional correlation with lecithin:cholesterol acyltransferase
19. Cholesterol efflux from macrophages and other cells
20. Lipoprotein composition of human suction-blister interstitial fluid
21. Altered epitope expression of human interstitial fluid apolipoprotein A-I reduces its ability to activate lecithin cholesterol acyltransferase
22. Interstitial fluid apolipoprotein A-II: An association with the occurrence of myocardial infarction
23. Gastric digestion modifies absorption of butterfat into lymph chylomicrons in rats
24. The anatomy and physiology of reverse cholesterol transport
25. Interstitial fluid lipoproteins
26. Isolation, characterization, and assay of lecithin-cholesterol acyltransferase
27. Mechanisms of action of lecithin-cholesterol acyltransferase
28. Lysolecithin acyltransferase of human plasma: Assay and characterization of enzyme activity
29. Preparation, characterization, and measurement of lipoprotein lipase
30. Preparation, characterization, and measurement of hepatic lipase
31. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis
32. Purification and characterization of a human plasma cholesteryl ester transfer protein
33. Isolation and specificity of a Mr 74,000 cholesteryl ester transfer protein from human plasma
34. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport
35. Isolation and characterization of a phospholipid transfer protein (LTP-II) from human plasma
36. Structure and function of the plasma phospholipid transfer protein
37. Chapter 18: Dynamics of lipoprotein transport in the human circulatory system
38. Cholesterol ester transfer protein: A molecule with three faces?
39. Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I
40. The molecular pathology of lecithin:cholesterol acyl-transferase (LCAT) deficiency syndromes
41. Reverse cholesterol transport: Its contribution to cholesterol catabolism in normal and disease states
42. Role of cholesterol in regulating apolipoprorein B secretion by the liver
43. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency
44. Extracellular space structure revealed by diffusion analysis
45. Perivascular spaces in the basal ganglia of the human brain: Their relationship to lacunes
46. Changes in brain gene expression shared by scrapie and Alzheimer's disease
47. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat
48. Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death
49. Analysis of differentially expressed genes in retinitis pigmentosa retinas. Altered expression of clusterin mRNA
50. SP-40,40 immunoreactivity in inflammatory CNS lesions displaying astrocyte/oligodendrocyte interactions
51. Astrocytic messenger RNA responses to striatal deafferentation in male rat
52. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning
53. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes
54. Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients
55. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats
56. Immunohistochemical study of α2 macroglobulin receptor in Alzheimer and control postmortem human brain
57. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
58. Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and in Alzheimer's disease
59. Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease
60. Upregulation of the macrophage scavenger receptor in response to different forms of injury in the CNS
61. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
62. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
63. Apolipoprotein E polymorphism and Alzheimer's disease
64. Introduction to the plasma lipoproteins
65. Nascent astrocyte particles differ from lipoproteins in CSF
66. Comparative analysis of mammalian plasma lipoproteins
67. The effect of subfractions of high density lipoprotein on cholesterol efflux from cultured fibroblasts
68. Evidence for a lipoprotein carrier in human plasma catalysing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase activity
69. Preferential enrichment of large-sized very low density lipoprotein populations with transferred cholesteryl esters
70. Plasma cholesteryl ester transfer protein
71. Comparative study of phospholipid transfer activities mediated by cholesteryl ester transfer protein and phospholipid transfer protein
72. Different locations of cholesteryl transfer protein and phospholipid transfer protein activities in plasma
73. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis
74. Molecular and macromolecular specificity of human plasma phospholipid transfer protein
75. Pig plasma phospholipid transfer protein facilitates HDL interconversion
76. Human plasma phospholipid transfer protein causes high density lipoprotein conversion
77. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein
78. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: Evidence for particle fusion
79. Phospholipid transfer protein can transform reconstituted discoidal HDL into vesicular structures
80. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes
81. Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL
82. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice
83. High density lipoproteins and reverse cholesterol transport - Lessons from mutations
84. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein
85. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species
86. Plasma phospholipid mass transfer: Relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters
87. 2-macroglobulin receptors in the brain
88. LDL receptor-related protein: A multiligand receptor for lipoprotein and proteinase catabolism
89. Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands
90. LDL-receptor structure: Calcium cages, acid baths and recycling receptors
91. Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family
92. 2-macroglobulin receptor-associated protein
93. Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian LDL receptor family member
94. cDNA cloning of a new low-density lipoprotein receptor-related protein and mapping of its gene (LRP3) to chromosome bands 19q12-q13.2
95. A novel low-density lipoprotein receptor-related protein with type II membrane protein-like structure is abundant in heart
96. Cloning of a novel member of the low-density lipoprotein receptor family
97. A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E
98. Isolation and characterization of apolipoprotein B-100
99. Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100
100. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin
101. Scavenger receptor family proteins: Roles for atherosclerosis, host defence and disorders of the central nervous system
102. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
103. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake
104. Dissociation of tissue uptake of cholesterol ester from that of apolipoprotein A-I of rat plasma high density lipoprotein: Selective delivery of cholesterol ester to liver, adrenal, and gonad
105. On the origin of the lipoproteins in the cerebrospinal fluid
106. Apolipoproteins in human cerebrospinal fluid
107. SP-40,40 is a constituent of Alzheimer's amyloid
108. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid
109. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid
110. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain
111. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid - Association with high-density lipoproteins
112. General properties of plasma lipoproteins and apolipoproteins. Appendix 2
113. Metabolism of apolipoprotein C
114. Isolation and partial characterization of apolipoprotein D: A new protein moiety of the human plasma lipoprotein system
115. Isolation and characterization of apolipoprotein E
116. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis
117. Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes
118. Clinical relevance of the quantitation of apolipoprotein E in cerebrospinal fluid
119. A sensitive time-resolved immunofluorometric assay for the measurement of apolipoprotein B in cerebrospinal fluid. Application to multiple sclerosis and other neurological diseases
120. Apolipoprotein A-IV acts centrally in the brain to reduce the severity of gastric ulceration in the rat
121. Expression of apolipoprotein A-I in porcine brain endothelium in vitro
122. Synthesis of apolipoprotein A-I in pig brain microvascular endothelial cells
123. Localization of sulfated glycoprotein-2/clusterin mRNA in the rat brain by in situ hybridization
124. Expression in mouse embryos and in adult mouse brain of three members of the amyloid precursor protein family, of the alpha-2-macroglobulin receptor/low density lipoprotein receptor-related protein and of its ligands apolipoprotein E, lipoprotein lipase, alpha-2-macroglobulin and the 40,000 molecular weight receptor-associated protein
125. Purification and characterization of brain clusterin
126. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation
127. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid β
128. Lecithin:cholesterol acyltransferase activity in human cerebrospinal fluid
129. Evidence for two cholesterol ester hydrolases in human cerebrospinal fluid
130. Cholesteryl ester transfer protein in human brain
131. Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid
132. An electrophoretic method for the quantitative isolation of human and swine plasma lipoproteins
133. Obligatory role of cholesterol and apolipoprotein E in the formation of large cholesterol-enriched and receptor-active high density lipoproteins
134. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
135. Factors affecting the integrity of high density lipoproteins in the ultracentrifuge
136. Evidence for the distribution of apolipoprotein E between lipoprotein classes in human normocholesterolemic plasma and for the origin of unassociated apolipoprotein E (Lp-E)
137. Evidence for high density lipoproteins as the major apolipoprotein A-IV-containing fraction in normal human serum
138. Distribution of the alpha-2-macroglobulin receptor/low density lipoprotein-related receptor protein in human tissues
139. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
140. Structure and stability of apolipoprotein J-containing high-density lipoproteins
141. The esential fatty acids
142. Lipids of nervous tissue: Composition and metabolism
143. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve
144. Formation of unesterified choline by rat brain
145. Presence of base-exchange activity in rat brain nerve endings: Dependence on soluble substrate concentrations and effect of cations
146. In situ hybridization histochemistry and the study of gene expression in the human brain
147. Characterization of messenger RNA from the cerebral cortex of control and Alzheimer-afflicted brain
148. A comparison of methodologies for the study of functional transmitter neurochemistry in human brain
149. Terminal coma affects messenger RNA detection in post mortem human temporal cortex
150. Advances in post mortem molecular neurochemistry and neuropathology: Examples from schizophrenia research
151. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
152. The role of apolipoprotein E in the nervous system
153. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets
154. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease
155. Apolipoprotein E and Alzheimer's disease: A review of recent studies
156. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease
157. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro
158. Cis-acting human apoE tissue expression element is associated with human pattern of intraneuronal apoE in transgenic mice
159. Regionally specific neuronal expression of human APOE gene in transgenic mice
160. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: A light and electron microscopic study
161. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls
162. Pattern of apolipoprotein E imunoreactivity during brain aging
163. Clusterin and apolipoprotein E gene expression in the adult brain
164. Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain
165. Clusterin: An enigmatic protein recruited by diverse stimuli
166. Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells
167. Apolipoprotein J: Structure and tissue distribution
168. The primary structure of glycoprotein III from bovine adrenal medullary chromaffin granules
169. Expression of porcine complement cytolysis inhibitor mRNA in cultured aortic smooth muscle cells. Changes during differentiation in vitro
170. Murine clusterin: Molecular cloning and mRNA localization of a gene associated with epithelial differentiation processes during embryogenesis
171. Clusterin (SGP-2): A multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain
172. Lack of correspondence between mRNA expression for a putative cell death molecule (SGP-2) and neuronal cell death in the central nervous system
173. Protein SP40,40-like immunoreactivity in the rat brain: Progressive increase with age
174. Clusterin levels increase during neuronal development
175. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP)
176. Distribution of clusterin in Alzheimer brain tissue
177. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease
178. Cloning and expression of human apolipoprotein D cDNA
179. Identification, characterization, and tissue distribution of apolipoprotein D in the rat
180. Binding properties of progesterone-binding cyst protein PBCP
181. Is apolipoprotein D a mammalian bilin-binding protein?
182. Arachidonic acid binds to apolipoprotein D: Implications for the protein's function
183. A human axillary odorant is carried by apolipoprotein D,
184. Molecular characterization and differential mRNA tissue distribution of rabbit apolipoprotein D
185. Cellular localization of apolipoprotein D and lecithin:cholesterol acyltransferase mRNA in rhesus monkey tissues by in situ hybridization
186. Molecular characterization and differential mRNA tissue distribution of mouse apolipoprotein D
187. Pattern of apolipoprotein D immunoreactivity in human brain
188. Astrocytes synthesize and secrete the lipophilic ligand carrier apolipoprotein D
189. Activation of lecithin-cholesterol acyltransferase by apolipoprotein D: Comparison of proteoliposomes containing apolipoprotein D, A-I or C-I
190. Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene
191. Two coding regions closely linked to the rat apolipoprotein E gene: Nucleotide sequences of rat apolipoprotein C-I and ECL cDNA
192. Structure and expression of dog apolipoprotein A-I, E, and C-I mRNAs: Implications for the evolution and functional constraints of apolipoprotein structure
193. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein
194. Effect of apolipoprotein C-I peptides on the apolipoprotein E content and receptor-binding properties of beta-migrating very low density lipoproteins
195. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver
196. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway
197. The apolipoprotein CI A allele as a risk factor for Alzheimer's disease
198. A closely linked gene to apolipoprotein E may serve as an additional risk factor for Alzheimer's disease
199. Genetic association study between senile dementia of Alzheimer's type and APOE/C1/C2 gene cluster
200. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease
201. The plasma lecithin:cholesterol acyltransferase protein
202. Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol
203. Lecithin:cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits
204. Chicken lecithin-cholesterol acyltransferase. Molecular characterization reveals unusual structure and expression pattern
205. A protein cofactor of lecithin:cholesterol acyltransferase
206. A cholesterol-esterifying enzyme in rat central nervous system myelin
207. Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer's disease brain tissues
208. Separation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein
209. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet
210. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes
211. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis
212. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein
213. Glycoprotein 330, a member of the low density lipoprotein receptor family, binds lipoprotein lipase in vitro
214. Spinal cord of the rat contains more lipoprotein lipase than other brain regions
215. Lipoprotein lipase activity in developing rat brain areas
216. Lipoprotein lipase mRNA in neonatal and adult mouse tissues: Comparison of normal and combined lipase deficiency (cld) mice assessed by in situ hybridization
217. Low density lipoprotein-receptors in primary cultures of rat glial cells
218. Infection of brain microglial cells by human immunodeficiency virus type I is CD4 dependent
219. Very low density lipoprotein receptor and Alzheimer's disease
220. Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain
221. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain
222. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein
223. Subcellular localization of the low density lipoprotein receptor-related protein (alpha2-macroglobulin receptor) in human brain
224. Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons
225. Expression and distribution of low density lipoprotein receptor-related protein mRNA in the rat central nervous system
226. Apolipoprotein E and apolipoprotein E receptors in the central nervous system: Relationship with Alzheimer's disease
227. Regulation of clusterin secretion and mRNA expression in astrocytes by cytokines
228. Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures
229. Expression of apolipoprotein E mRNA in rat microglia
230. Oligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerve
231. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts
232. Secretion of apolipoprotein E by an astrocytoma cell line
233. Radioimmunoassay of human high density lipoprotein apo-protein A-1
234. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: Astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins
235. Lipoprotein secretion by primary astrocytes from wild type, apoE null and human apoE transgenic mice
236. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces diferrential effects on neurite outgrowth
237. A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins
238. Lipoprotein uptake by neuronal growth cones in vitro
239. Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro
240. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro
241. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived cell line
242. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein
243. β-Amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons
244. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma
245. β-Amyloid associates with CNS lipoproteins
246. The cell biology of myelin degeneration and regeneration in the peripheral nervous system
247. Fatty acids from degenerating myelin lipids are conserved and reutilized for myelin synthesis during regeneration in peripheral nerve
248. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
249. Apolipoprotein E: Cholesterol transport protein with expending role in cell biology
250. Lipid metabolism during early stages of Wallerian degeneration in the rat sciatic nerve
251. Schwann cell properties: 3. C-fos expression, bFGF production, phagocytosis and proliferation during Wallerian degeneration
252. Wallerian degeneration in the peripheral nervous system: Participation of both Schwann cells and macrophages in myelin degradation
253. Fate of myelin lipids during degeneration and regeneration of peripheral nerve: An autoradiographic study
254. Cholesterol synthesis is down-regulated during regeneration of peripheral nerve
255. Cholesterol from degenerating nerve myelin becomes asociated with lipoproteins containing apolipoprotein E
256. Reutilization of cholesterol-1-2-3H in the regeneration of the peripheral nerve
257. Wallerian degeneration of rat sciatic nerve. Changes in cholesteryl ester content and fatty acid composition
258. Wallerian degeneration in the rat. A chemical study
259. Fine structural localization of cholesterol-1-2-3H in degenerating and regenerating mouse sciatic nerve
260. The sequential alterations of endoneurial cholesterol and fatty acid in Wallerian degeneration and regenertion
261. Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve: Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E and apolipoprotein A-I
262. Lipid and protein changes in sciatic nerve during Wallerian degeneration
263. Metabolic turnover of fatty acids and acylglycerols in rat sciatic nerve
264. Cholesterol esterifying enzyme in normal and degenerating peripheral nerve
265. Apolipoprotein E is released by sciatic nerve during segmental demyelination and remyelination
266. Expression of apolipoprotein E during nerve degeneration and regeneration
267. Apolipoprotein E in nerve injury and repair
268. Denervated sheath cells secrete a new protein after a nerve injury
269. Characterization of the 37 kD protein associated with nerve development and injury
270. Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells
271. Plasma lipoproteins: Apolipoprotein structure and function
272. Macrophage-like cells from explant cultures of rat sciatic nerve produce apolipoprotein E
273. A specific 37,000-dalton protein that accumulates in regenerating but not non-regenerating mammalian nerve
274. Expression of clusterin and C4 mRNA during rat peripheral nerve regeneration
275. Regeneration-associated high level expression of apolipoprotein D mRNA in endoneurial fibroblasts of peripheral nerve
276. Expression of specific sheath cell proteins during peripheral nerve growth and regeneration in mammals
277. Apolipoproteins in human cerebrospinal fluid
278. Response of striatal astrocytes to neuronal deafferentation: An immunohistochemical and ultrastructural study
279. Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus
280. Astroglial gene expression during reactive synaptogenesis
281. Differential regulation of astrocytic mRNAs in the rat striatum after lesions of the cortex or substantia nigra
282. Modulation of apolipoprotein D and apoE mRNA expression in rat entorhinal cortex lesion
283. Clusterin accumulates in dying neurons following status epilepticus
284. Sulfated glycoprotein-2 is increased in rat hippocampus following entorhinal cortex lesion
285. Sulfated glycoprotein 2: New relationship of this multifunctional protein to neurodegeneration
286. Effect of chronic adrenalectomy on neuron loss and distribution of sulfated glycoprotein-2 in the dentate gyrus of prepubertal rats
287. Possible function of a new genetic marker in the central nervous system: The sulfated glycoprotein-2 (SPG-2)
288. Sulfated glycoprotein-2 (SPG-2) mRNA is expressed in rat striatal astrocytes following ibotenic acid lesions
289. Clusterin (SPG-2): A multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain
290. Seizure activity causes a rapid increase in sulfated glycoprotein-2 messenger RNA in the adult but not the neonatal rat brain
291. Sulfated glycoprotein-2 mRNA in the rat following transient forebrain ischemia
292. Increases in sulfated glycoprotein-2 mRNA levels in the rat brain after transient forebrain ischemia or partial mesodiencephalic hemitransection
293. Apolipoprotein D increases in rat hippocampus following entorhinal cortex lesioning
294. Dynamics of gene expression for hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat
295. Marked increases in concentrations of apolipoprotein in the cerebrospinal fluid of poliovirus-infected macaques: Relations between apolipoprotein concentrations and severity of brain injury
296. ApoA-I and apoE concentrations in cerebrospinal fluids of patients with acute meningitis
297. Aged apoE deficient mice: Abnormal learning and glial markers but no obvious neuropathology
298. Lesion-induced axon sprouting in the deafferented striatum of adult rat
299. Hydrolysis and excretion of cytoplasmic cholesteryl esters by macrophages: Stimulation by high density lipoprotein and other agents
300. Formation of cholesterol- and apoprotein E-enriched high density lipoproteins in vitro
301. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells
302. Receptor-mediated endocytosis: Concepts emerging from the LDL receptor system
303. Modulators of neuronal migration and neurite growth
304. Inverse pattern of myelination and GAP-43 expression in the adult CNS: Neurite growth inhibitors as regulators of neuronal plasticity?
305. Inhibitors of neurite growth
306. Reactive synaptogenesis in the hippocampus
307. Synapse replacement in the nervous system of adult vertebrates
308. Lesion-induced plasticity of central neurons: Sprouting of single fibres in the rat hippocampus after unilateral entorhinal cortex lesion
309. Reorganization of neuronal circuitry following central nervous system trauma: Naturally occuring processes and opportunities for therapeutic intervention
310. The process of reinnervation in the dentate gyms of the adult rat: A quantitative electron microscopic analysis of the terminal proliferation and reactive synaptogenesis
311. An electron microscopic study of lesion-induced synaptogenesis in the dentate gyms of the adult rat. I. Magnitude and time course of degeneration
312. Lesion-induced synapse growth in the hippocampus: In search of cellular and molecular mechanisms
313. The process of reinnervation in the dentate gyrus of adult rats: An ultrastructural study of changes in presynaptic terminals as a result of sprouting
314. Ultrastructural evidence for bouton proliferation in the partially deafferentated dentate gyrus of the adult rat
315. Astrocytes and microglial cells incorporate degenerating fibers following entorhinal lesion: A light, confocal, and electron microscopical study using a phagocytosis-dependent labeling technique
316. Astrocytes are important for sprouting in the septohippocampal circuit
317. Signals that induce sprouting in the central nervous system: Sprouting is delayed in a strain of mouse exhibiting delayed axonal degeneration
318. Neuronal activity up-regulates astroglial gene expression
319. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system
320. The low-density lipoprotein receptor-related protein, a multifunctional apolipoprotein E receptor, modulates hippocampal neurite development
321. Receptor binding of an apolipoprotein E-rich subfraction of high density lipoprotein to rat and human brain membranes
322. Dissociation of apolipoprotein and apolipoprotein receptor response to lesion in the rat brain: An in situ hybridization study
323. Expression of apoE mRNA in rat microglia
324. Elevated phosphocholine and phosphatidylcholine following rat entorhinal cortex lesions
325. Plasticity of hippocampal circuitry in Alzheimer's disease
326. Reinnervation of the hypocampal perforant pathway zone in Alzheimer's disease
327. Alzheimer's disease: Membrane-associated metabolic changes
328. Nerve regeneration and cholesterol reutilization occur in the absence of apolipoproteins E and A-I in mice
329. Nerve regeneration occurs in the absence of apolipoprotein E in mice
330. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins
331. Apolipoprotein J: Structure and tissue distribution
332. A 70 kDa Apolipoprotein designated apoJ is a marker for subclasses of human plasma density lipoproteins
333. Clusterin (complement lysis inhibitor) forms a high density lipoprorein complex with apolipoprotein A-I in human plasma
334. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: A potential anti-atherogenic function?
335. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologus recombination in ES cells
336. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E
337. Neurodegeneration in the central nervous system of apoE-deficient mice
338. Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury
339. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice
340. Memory deficits in apolipoprotein E-deficient mice
341. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: Implications for early treatment of Alzheimer's disease
342. Cholinergic system and long term potentiation in memory-impaired apolipoprotein E deficient mice
343. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE
344. Severe learning deficits in apolipoprotein E-knockout mice in a water maze task
345. Abnormal synaptic regeneration in hAPP695 transgenic and apoE knock-out mice
346. Behavioral, physiological and morphological analysis of a line of apolipoprotein E knockout mouse
347. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE(-/-) mice but impaired clearance of axonal degeneration products following injury
348. Synaptic alterations in apolipoprotein E knockout mice
349. Brain sterol metabolism
350. Ubiquinone, dolichol, and cholesterol metabolism in aging and Alzheimer's disease
351. Lipid compositions of different regions of the human brain during aging
352. New concepts in brain cholesterol metabolism
353. Studies on the biosynthesis of glycolipides and other lipides of the brain
354. The turnover of myelin phosphatidylcholine and sphingomyelin in the adult rat brain
355. Lipid biosynthesis in the central nervous system in experimental allergic encephalomyelitis
356. 14 mevalonic acid into cholesterol and fatty acids of brain and liver 'in vitro'
357. 14 acid
358. 14C] mevalonic acid into adult rat brain squalene and cholesterol
359. Transfer of carbon atoms from mevalonate to n-fatty acids
360. Lipid metabolism
361. Lipid metabolism
362. Membrane lipids, selectively diminished in Alzheimer brtains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II)
363. Decreased myelin lipids in Alzheimer's disease and vascular dementia
364. Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type
365. White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia - Diagnostic and pathogenic aspects
366. Periventricular white matter luciencies in SDAT and healthy aging
367. Evidence for a membrane defect in Alzheimer disease brain
368. Reduced phosphoinositide concentration in anterior temporal cortex of Alzheimer's disease brains
369. Studies of phospholipid composition in Alzheimer's disease brain
370. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain
371. Neural membrane phospholipids in Alzheimer's disease
372. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease
373. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects
374. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content
375. Regulation of protein kinase C activity by various lipids
376. Breakdown of membrane phospholipids in Alzheimer's disease. Involvement of excitatory amino acid receptors
377. Plasmalogens, phospholipases A2 and signal transduction
378. Phospholipase A2 and its role in brain tissue
379. The preference of cholesterol for phosphatidylcholine in mixed phosphatidylcholine-phosphatidylethanolamine bilayers
380. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain
381. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease
382. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain
383. 2 activity
384. Elevated activities of lipases and lysophospholipases in Alzheimer's disease
385. Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell
386. Activation of phospholipase A2 by amyloid beta-peptides in vitro
387. The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer-type dementia patients
388. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro
389. Apolipoprotein E, oxidative stress and Ginkgo biloba extract (EGb 761) in Alzheimer's disease
390. Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease
391. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: Identity to sulfated glycoprotein 2, a constituent of rat testis fluid
392. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease
393. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer's disease
394. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease
395. Cytopathology of amyotrophic lateral sclerosis
396. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: A review
397. Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: Evidence for a major influence on the clinical presentation and prognosis
398. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's disease
399. Association of apolipoprotein E4 allele with bulbar-onset motor neuron disease
400. Apolipoprotein E e4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis
401. Macrophages in the peripheral nervous system and astroglia in the central nervous system of rat commonly express apolipoprotein E during development but differ in their response to injury
402. Distinct distribution of apolipoprotin E and beta-amyloid immunoreactivity in the hippocampus of Parkinson dementia complex of Guam
403. Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts
404. A defect in cholesterol esterification in certain patients designated as Niemann-Pick disease type C
405. Type C Niemann-Pick disease: A parallel loss of regulatory responses in both the uptake and esterification of LDL-derived cholesterol in cultured fibroblasts
406. Niemann-Pick disease, type C: A cellular cholesterol lipidosis
407. Neurofibrillary tangles in Niemann-Pick disease type C
408. Neurological mutation characterized by dysmyelination in NCTR-Balb/C mouse with lysosomal lipid storage disease
409. Pathology of Niemann-Pick type C: Studies of murine mutants
410. Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis
411. Murine model of Niemann-Pick C disease: Mutation in a cholesterol homeostasis gene
412. Niemann-Pick disease types C and D
413. Group C Niemann-Pick disease: Faulty regulation of low-density lipoprotein uptake and cholesterol storage in cultured fibroblasts
414. A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase
415. The low-density lipoprotein pathway and its relation to artherosclerosis
416. Is apolipoprotein D a mammalian bilin-binding protein?
417. Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein D
418. Types of multi-infarct dementia
419. Lipids, vascular disease, and dementia with advancing aging: Epidemiologic considerations
420. Multi-infarct dementia
421. Changes in brain and pial vessels in arterial border zones
422. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study
423. Lipoprotein and apolipoprotein profile in men with ischemic stroke: Role of lipoprotein (a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism
424. Apolipoprotein E epsilon 4 and the risk of dementia with stroke: A population-based investigation
425. Brain infarction and the clinical expression of Alzheimer disease
426. Apolipoprotein E genotypes and serum lipid levels in Alzheimer's disease and multi-infarct dementia
427. Apolipoprotein E polymorphism and atherosclerosis
428. Apolipoprotein E and atherosclerosis
429. The apolipoprotein E polymorphism: A comparison of allele frequencies and effects in nine populations
430. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health
431. Does apolipoprotein E genotype influence dietary modification of circulating cholesterol concentrations?
432. Women, myocardial infarction, and dementia in the very old
433. The influence of coincidental vascular pathology on symptomatology and course of Alzheimer's disease
434. Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils
435. Complete cerebral ischemia with short term survival in rat induced by cardiac arrest: Extracellular and intracellular accumulation of apolipoprotein E and J in brain
436. Apolipoprotein E deficient mice have increased susceptibility to focal cerebral ischemia
437. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice
438. ApoE genotype and survival from intracerebral haemorrhage
439. A large intracranial xanthomas in familial hypercholesterolemia
440. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice
441. Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding
442. Mouse models of atherosclerosis
443. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologus rcombinations in ES cells
444. Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding
445. Cerebral lipid deposition in aged apolipoprotein E-deficient mice
446. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E
447. Apolipoprotein E polymorphism and atherosclerosis
448. Type III hyperproteinemia associated with plasma apolipoprotein E deficiency
449. Apolipoprotein ε4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease
450. Treatment outcome of tacrine therapy depends on apolipoprotein E genotype and gender of the subject with Alzheimer's disease
451. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype in Alzheimer's disease patients
452. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease
453. Apo E genotype and clinical outcome in Alzheimer's disease
454. Can Apo-E4 subtype predict response to selegi-line treatment in Alzheimer's disease?
455. APOE genotyping and response to drug treatment in Alzheimer's disease
456. GFAP-apolipoprotein E (apoE) transgenic mice: Astroctye specific expression and differing biological effects of secreted apoE3 and apoE4 lipoproteins
457. Expression of human apolipoprotein E3 and E4 in the brains of apoE-/- mice: Isoform specific effects on neurodegeneration